IMRT

Kallisio Patient-tailored Oral Stent for Head and Neck Cancer (HNC) Treatment Receives FDA Clearance

Retrieved on: 
Thursday, January 18, 2024

Kallisio , focused on developing solutions to manage toxicity in cancer care, announces FDA 510(k) clearance for Stentra, an individually tailored 3D printed oral stent solution designed to protect healthy tissue in Head and Neck Cancer (HNC) patients.

Key Points: 
  • Kallisio , focused on developing solutions to manage toxicity in cancer care, announces FDA 510(k) clearance for Stentra, an individually tailored 3D printed oral stent solution designed to protect healthy tissue in Head and Neck Cancer (HNC) patients.
  • Customized for each patient, the Stentra oral immobilization stent effectively directs radiation to the target tumor area while reducing harmful impact to surrounding tissue.
  • By integrating patient oral data with advanced 3D printing, Stentra is meticulously tailored to mitigate target positioning discrepancies associated with radiotherapy methods like IMRT (intensity-modulated radiation therapy).
  • A Stentra device immobilizes tongue, lips, and other OARs (organs at risk), keeping them clear of the high-dose radiation target zone.

Open Letter to ViewRay Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global Companies

Retrieved on: 
Friday, October 13, 2023

TeamBest Global Companies (TBG) have been in business since 1951—over 70 years—with many innovations in Brachytherapy, Teletherapy, IMRT treatment planning software, Heavy Ion 400 MeV ion, Rapid Cycling Medical Synchrotron Proton-to-Carbon, a range of cyclotrons from 1 MeV to 200 MeV for research, Radioisotope Production, Proton Therapy, Theranostics/Targeted Systemic Radiation Therapy, Blood, Animal Cell and Research Irradiators, etc.

Key Points: 
  • TeamBest Global Companies (TBG) have been in business since 1951—over 70 years—with many innovations in Brachytherapy, Teletherapy, IMRT treatment planning software, Heavy Ion 400 MeV ion, Rapid Cycling Medical Synchrotron Proton-to-Carbon, a range of cyclotrons from 1 MeV to 200 MeV for research, Radioisotope Production, Proton Therapy, Theranostics/Targeted Systemic Radiation Therapy, Blood, Animal Cell and Research Irradiators, etc.
  • I am saddened by ViewRay’s recent announcement that their operations will soon cease and that after October, their customers may not be able to receive support for service, maintenance, quality and regulatory issues, upgrades, etc.
  • TBG Companies have 1000s of Teletherapy units—Cobalt 60 Gamma Beam with IMRT capabilities on some, and 1000 plus X Ray, Cesium 137 Blood, Animal, Cell and Research Irradiators, among other products.

Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Month

Retrieved on: 
Wednesday, October 4, 2023

During the call, Laurent Levy, chief executive officer, will review the Study 102 final data before taking questions from participants.

Key Points: 
  • During the call, Laurent Levy, chief executive officer, will review the Study 102 final data before taking questions from participants.
  • Surgery or definitive cisplatin-based chemotherapy are the current standard of care for patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC; head and neck cancer).
  • One third of these patients, however, cannot tolerate cisplatin due to complications such as age-related frailty or other medical conditions (comorbidities).
  • At the final readout, an independent review committee determined a median Progression-Free Survival (mPFS) of 16.9 months in evaluable patients.

NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer

Retrieved on: 
Thursday, September 28, 2023

PARIS and CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced new clinical data from a Phase 1 study evaluating radiotherapy-activated NBTXR3 for patients with pancreatic ductal adenocarcinoma (PDAC). The study is being conducted as part of an ongoing collaboration between Nanobiotix and The University of Texas MD Anderson Cancer Center (MD Anderson) and results were presented at the American Association for Cancer Research (AACR) 2023 Special Conference on Pancreatic Cancer.

Key Points: 
  • For the more than 90% of patients with locally advanced disease that is not eligible for surgery (unresectable), there are few treatment options with curative intent.
  • As such, the 5-year overall survival rate for patients with unresectable PDAC remains less than 5%.
  • These patients present an urgent unmet need for new treatment options that provide effective local control with tolerable safety profiles.
  • The Company believes these results support the rationale for further development of NBTXR3 in pancreatic cancer.

Long-term Outcomes of Radiation Techniques for Locally Advanced Non-Small Cell Lung Cancer Presented at IASLC 2023 Conference in Singapore

Retrieved on: 
Tuesday, September 12, 2023

OAK BROOK TERRACE, Ill., Sept. 12, 2023 /PRNewswire-PRWeb/ -- Intensity-modulated radiation therapy, or IMRT, should be utilized for locally advanced NSCLC to reduce the risk of severe pulmonary toxicity and radiation exposure to the heart, according to research presented today at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer in Singapore.

Key Points: 
  • Intensity-modulated radiation therapy, or IMRT, should be utilized for locally advanced NSCLC to reduce the risk of severe pulmonary toxicity and radiation exposure to the heart, according to research presented today at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer in Singapore.
  • OAK BROOK TERRACE, Ill., Sept. 12, 2023 /PRNewswire-PRWeb/ -- Intensity-modulated radiation therapy, or IMRT, should be utilized for locally advanced NSCLC to reduce the risk of severe pulmonary toxicity and radiation exposure to the heart, according to research presented today at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer in Singapore.
  • Concurrent photon-based chemoradiation is an established standard of care for unresectable locally advanced non-small cell lung cancer (NSCLC), However, the choice between IMRT and 3D-CRT has remained contentious due to limited prospective data.
  • The secondary analysis of NRG Oncology-RTOG 0617, spanning a median follow-up of 5.2 years, involved 482 patients with locally advanced NSCLC.

Global Radiation Therapy Market Forecast Report 2023-2027: A $13.28 Billion Market in 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 26, 2023

The "Global Radiation Therapy Market with Focus on LINAC: Insights & Forecast (2023-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Radiation Therapy Market with Focus on LINAC: Insights & Forecast (2023-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The global radiation therapy market is expected to reach US$13.28 billion in 2027, witnessing growth at a CAGR of 6.77%, over the period 2023-2027.
  • The global radiation therapy market can be categorized into external beam radiation therapy, internal beam radiation therapy and others (systemic radiotherapy) on the basis of type.
  • Depending upon the type, the global external beam radiation therapy market can be categorized into following categories: Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), Tomotherapy, Stereotactic Radiosurgery, Stereotactic Body Radiation Therapy and Proton Therapy.

Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting

Retrieved on: 
Monday, June 5, 2023

MALVERN, Pa., June 05, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today presented data from the Phase 3 ROMAN trial demonstrating avasopasem manganese (avasopasem) improved preservation of kidney function and reduced cisplatin-related chronic kidney disease (CKD) in patients with head and neck cancer (HNC) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Patients in the ROMAN trial received standard-of-care radiation therapy with concurrent cisplatin. These kidney results are in addition to the ROMAN data showing a significant reduction in severe oral mucositis (SOM) in these patients, which form the basis of the avasopasem New Drug Application (NDA) currently under priority review with the U.S. Food and Drug Administration (FDA).

Key Points: 
  • Patients in the ROMAN trial received standard-of-care radiation therapy with concurrent cisplatin.
  • These kidney results are in addition to the ROMAN data showing a significant reduction in severe oral mucositis (SOM) in these patients, which form the basis of the avasopasem New Drug Application (NDA) currently under priority review with the U.S. Food and Drug Administration (FDA).
  • Our Phase 3 ROMAN trial demonstrated avasopasem’s ability to reduce SOM, a debilitating toxicity induced by radiotherapy, and our NDA for this indication is currently under FDA priority review.
  • The effect of avasopasem on kidney function was assessed throughout treatment and every three months for one year following seven weeks of therapy.

RayCare is interoperable with Varian TrueBeam

Retrieved on: 
Wednesday, May 24, 2023

STOCKHOLM, May 24, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) is proud to announce that the oncology information system RayCare®* can connect to Varian TrueBeam® linear accelerators.

Key Points: 
  • STOCKHOLM, May 24, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) is proud to announce that the oncology information system RayCare®* can connect to Varian TrueBeam® linear accelerators.
  • This kind of bi-lateral connection is referred to as interoperability, and after an extensive program with joint development and testing, Varian has now certified that RayCare is interoperable with the TrueBeam platform.
  • This applies to all linacs in the TrueBeam family: TrueBeam, TrueBeam STx, Edge and VitalBeam.
  • Johan Löf, founder and CEO, RaySearch, says: "As previously communicated, achieving interoperability between RayCare and TrueBeam has taken longer than originally planned.

Hackensack Meridian Health Invests $14 Million Into Oncology Expansion at JFK University Medical Center

Retrieved on: 
Friday, March 17, 2023

EDISON, N.J., March 17, 2023 /PRNewswire/ -- Hackensack Meridian Health is proud to announce it is investing $14 million dollars at JFK University Medical Center to expand access to state-of-the-art oncology services.

Key Points: 
  • EDISON, N.J., March 17, 2023 /PRNewswire/ -- Hackensack Meridian Health is proud to announce it is investing $14 million dollars at JFK University Medical Center to expand access to state-of-the-art oncology services.
  • "Our investment in JFK University Medical Center will strengthen patient access to specialized oncology services and meet their future healthcare needs," said Todd Way, president, central market, Hackensack Meridian Health.
  • The new state-of-the-art oncology facility at JFK University Medical Center will be located in a separate building across the street from the main hospital at 80 James Street.
  • "This new expansion will double the size of the existing infusion capabilities currently offered to our patients," said Joseph Landolfi, D.O., CPE, chief medical officer, JFK University Medical Center.

RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment

Retrieved on: 
Wednesday, January 18, 2023

The TIGeR-PaC clinical trial is evaluating intra-arterial (IA) administration of gemcitabine (chemotherapy) using the proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) platform for targeted treatment of Locally Advanced Pancreatic Cancer (LAPC).

Key Points: 
  • The TIGeR-PaC clinical trial is evaluating intra-arterial (IA) administration of gemcitabine (chemotherapy) using the proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) platform for targeted treatment of Locally Advanced Pancreatic Cancer (LAPC).
  • The substudy concludes that RenovoTAMP may increase local gemcitabine concentration, which may be beneficial in decreasing gemcitabine-related systemic side effects.
  • “Targeted local delivery of standard dose gemcitabine via the RenovoTAMP therapy platform may be associated with significantly less systemic drug exposure.
  • The poster presentations for the four RenovoRx abstracts to be presented at the ASCO GI Symposium will be available on RenovoRx’s website once available: https://renovorx.com/for-clinicians/ .